NEO Neogenomics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NEO

Price (delayed)

$16.545

Market cap

$2.14B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.24

Enterprise value

$2.45B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 40

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, ...

Highlights
The company's EPS has surged by 73% YoY and by 38% QoQ
The net income has soared by 72% YoY and by 38% from the previous quarter
NEO's debt is up by 9% YoY
The quick ratio has contracted by 7% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.neogenomics.com
Peers: RDNT DGX LH

Key stats

What are the main financial stats of NEO

NEO stock price

How has the Neogenomics stock price performed over time
Intraday
-1.69%
1 week
0.33%
1 month
2.13%
1 year
65.45%
YTD
40.69%
QTD
-9.89%

Financial performance

How have Neogenomics's revenue and profit performed over time
Revenue
$787.75M
Gross profit
$352.67M
Operating income
-$49.37M
Net income
-$32.3M
Gross margin
44.8%
Net margin
-4.1%
NEO's net margin has soared by 74% YoY and by 40% QoQ
The net income has soared by 72% YoY and by 38% from the previous quarter
Neogenomics's operating margin has soared by 63% YoY and by 29% from the previous quarter
The company's operating income has surged by 59% YoY and by 28% QoQ

Price vs fundamentals

How does NEO's price correlate with its fundamentals

Growth

What is Neogenomics's growth rate over time

Valuation

What is Neogenomics stock price valuation
NEO P/E details
P/E
N/A
P/B
2.65
P/S
2.7
EV/EBIT
N/A
EV/EBITDA
62.14
EV/Sales
3.11
The company's EPS has surged by 73% YoY and by 38% QoQ
The price to book (P/B) is 42% more than the 5-year quarterly average of 1.9 and 29% more than the last 4 quarters average of 2.1
The equity is down by 4.5% year-on-year
The price to sales (P/S) is 25% higher than the last 4 quarters average of 2.2 but 5% lower than the 5-year quarterly average of 2.9
The revenue rose by 11% YoY and by 2.8% QoQ

Efficiency

How efficient is Neogenomics business performance
The company's return on sales has surged by 73% YoY and by 38% QoQ
NEO's ROIC has soared by 71% year-on-year and by 39% since the previous quarter
The return on equity has surged by 69% year-on-year and by 37% since the previous quarter
The return on assets has surged by 68% year-on-year and by 37% since the previous quarter

Dividends

What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NEO.

Financial health

How did Neogenomics financials performed over time
The total assets is 139% greater than the total liabilities
NEO's current ratio is down by 10% YoY
Neogenomics's total liabilities has increased by 7% YoY
NEO's debt is 44% lower than its equity
The debt to equity rose by 14% year-on-year
NEO's debt is up by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.